Showing 2061-2070 of 3223 results for "".
- Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eyehttps://modernod.com/news/alcon-survey-shows-more-screen-time-causing-consumer-concern-about-eye-health-increasing-symptoms-of-dry-eye/2478054/Alcon announced the results of a new survey, conducted by research firm Ipsos among 1,005 US adults, that uncover the impact the COVID-19 pandemic is having on consumers’ screen time and how that impacts their perceptions on eye health. Key findings include: Nearly 80% of Americans r
- Alcon to Showcase Latest Innovations, Data at ASRS 2020 Virtual Annual Meetinghttps://modernod.com/news/alcon-to-showcase-latest-innovations-data-at-asrs-2020-virtual-annual-meeting/2478040/Alcon will present key data highlighting advancements in vitreoretinal surgery during the American Society of Retina Specialists (ASRS) 2020 virtual annual meeting, taking place July 24-26. New data about the effectiveness of the Hypervit Dual Blade Vitrectomy Probe and other retina surgical plat
- Moderna’s COVID-19 Vaccine Candidate Induces “Robust” Response In All Patients Testedhttps://modernod.com/news/modernas-covid-19-vaccine-candidate-induces-robust-response-in-all-patients-tested/2478023/The NEJM published an interim analysis Tuesday of an ongoing phase 1 trial showing that Moderna’s experimental COVID-19 vaccine mRNA-1273 induced anti–SARS-CoV-2 immune responses in all participants, with the authors saying there were “no trial-limiting safety concerns.”
- Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strengthhttps://modernod.com/news/alcon-announces-fda-approval-of-the-otc-switch-of-pataday-once-daily-relief-extra-strength/2478016/Alcon announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, has been approved by the FDA for sale over-the-counter (OTC) in the United States. Pataday Once Daily Relief Extra Strength is the first and only once
- HHS Allocates Another $4B in COVID-19 Relief Funds to Rural Facilities, Safety Net Hospitalshttps://modernod.com/news/hhs-allocates-another-4b-in-covid-19-relief-funds-to-rural-facilities-safety-net-hospitals/2478004/The Department of Health and Human Services (HHS) is allocating approximately $3 billion to safety net hospitals and another $1 billion in COVID-19 relief funds to certain rural providers and others in small metropolitan areas, according to a FierceHealthcare
- Refractive Surgery Alliance to Raise Awareness of Global Vision Correction Monthhttps://modernod.com/news/refractive-surgery-alliance-to-raise-awareness-of-global-vision-correction-month/2477990/July is Global Vision Correction Month and members of the Refractive Surgery Alliance (RSA) will celebrate by sharing their own vision correction surgery to raise awareness on social media, television and on the web. “We are seeing a 11.8% incr
- Quantel Medical Completes Acquisition of Ellexhttps://modernod.com/news/quantel-medical-completes-acquisition-of-ellex/2477963/Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT and iTrack), via the financial holding company Lumibird Medical.
- Hospitals in New COVID-19 Hot Spots Face Delicate Balancing Act With Elective Surgerieshttps://modernod.com/news/hospitals-in-new-covid-19-hot-spots-face-delicate-balancing-act-with-elective-surgeries/2477955/Some hospital systems located in states that are seeing huge spikes of COVID-19 are continuing to perform elective procedures and developing strategies to avoid a total shutdown, according to a FierceHealthcare
- After Sale of Ellex Medical Lasers, Nova Eye Medical is Formedhttps://modernod.com/news/nova-eye-medical-launches-to-propel-glaucoma-innovation/2477952/Ellex Medical Lasers has completed the sale of its Ellex Lasers & Ultrasound business to Quantel Medical via Lumibird Group SA, and changed its name from Ellex Medical Lasers Limited to Nova Eye Medical Limited. In December 2019, Lumibird Group, the parent company of Quantel Medical, s
- Santen and Singapore’s Health-Tech Start-up, Plano, Form a Strategic Alliance to Tackle the Global Burden of Myopiahttps://modernod.com/news/santen-and-singapores-health-tech-start-up-plano-form-a-strategic-alliance-to-tackle-the-global-burden-of-myopia/2477947/Santen Pharmaceutical and Plano announced a strategic alliance to tackle the global burden of myopia. Under the alliance, Plano has secured an investment from Santen with the goal of tackling the burden of myopia using both a holistic approach and innovative technological solutions. “